Please assess the completion status of the following clinical trial:

Trial Title: Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* All patients who, after IVF-PGT-A treatment with their own oocytes, present a euploid embryo for transfer.~* Transfer of a single euploid embryo~Exclusion criteria:~* Moderate or high smoking (\> 5 cigarettes/day)~* BMI ≥30 kg/m2~* Chronic hypertension~* History of preeclampsia in previous pregnancies~* History of delayed uterine growth and placental insufficiency in previous pregnancies~* Use of donor sperm~* Woman's age ≥44 years~* Women with menstrual cycles longer than 35 days

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- FROZEN EMBRYO TRANSFER IN NATURAL CYCLE (Type: NO_INTERVENTION): After confirming ovarian rest (follicles \< 10 mm) with menstruation by means of vaginal ultrasound, an ultrasound control of the natural cycle will be carried out, inducing ovulation when an ovulatory follicle of size ≥ 17mm and an endometrium ≥ 7mm are found. Serum estradiol and progesterone values will be determined that day. This induction will be carried out with an ampoule of 250 μg of rHCG (Ovitrelle®). After the injection of Ovitrelle®, the administration of micronized vaginal progesterone (Progeffik® or Utrogestan®) 200 mg/ 12 hours and 7 days after the injection, thawing and transfer of a frozen euploid blastocyst will begin 48 hours later.
- FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE (Type: ACTIVE_COMPARATOR): After confirming ovarian rest (follicles \< 10 mm) with menstruation by vaginal ultrasound, hormone replacement therapy with oestrogens (6 mg/day of oral oestradiol valerate - Progynova® or Progyluton®- or 150 ug/48 h of oestradiol in patches - Evopad®) will be started on day 2-3 of the cycle. On day 10-15 of treatment an ultrasound scan will be performed to assess endometrial growth and ovarian rest. After confirming an endometrial thickness ≥ 7mm by vaginal ultrasound, ovaries with follicles smaller than 10 mm, blood estradiol \>100 pg/ml and serum progesterone \< 1 ng/ml, luteal phase support will begin with the administration of 400 mg of micronized vaginal progesterone every 12 hours, a total of 10 shots, prior to embryo transfer of a thawed euploid blastocyst. same day. If the level of serum progesterone on the day of transfer is less than 9.2 ng/ml, a daily injection of subcutaneous progesterone (Prolutex®) will be added on the same day.

Based on this trial design, predict the completion outcome and termination type (if applicable).